Thank you, Mr. Chair.
On behalf of the Juveniles Diabetes Research Foundation, I'd like to thank the committee for the opportunity to present this morning. My name is Andrew McKee, and I'm the president and the CEO of JDRF Canada.
The Juvenile Diabetes Research Foundation is the leading charitable funder and advocate for type 1 diabetes research worldwide. Our mission is to find a cure for diabetes and its complications through the support of research. As such, we have been a strong voice for innovation, commercialization, and increased funding for research and development—all areas of Canadian pride and excellence.
In the last ten years, JDRF has funded over $95 million worth of diabetes research here in Canada. On behalf of our entire organization, the families who live with the burden of diabetes, I'd like to express our sincere appreciation of this committee's continued interest in and support for our cause. In 2008 this committee recommended that the federal government create a specialized fund for medical research for children's health and that in this regard priority should be given to the establishment of a partnership with the Juveniles Diabetes Research Foundation of Canada.
We're pleased to be able to report to this committee that on November 23 of last year, JDRF Canada, along with the Federal Economic Development Agency for Southern Ontario, launched the government's first partnership to benefit diabetes and the diabetes research community. The Government of Canada has committed $20 million as part of a $33.9-million partnership with JDRF to support the development of the Canadian Clinical Trial Network. The network's aim is to accelerate research advances for type 1 diabetes by capitalizing on southern Ontario's well-established leadership in medical research and innovation.
This initiative marks a pivotal achievement of our organization and is the significant first step in positioning Canada as the premier hub and home for international, cutting-edge diabetes research. Since last year's announcement, we are pleased to report that significant progress has been made in achieving our goal. In March 2010 we announced that the University of Waterloo, in alliance with McMaster University, and additionally since then the Robarts Research Institute at the University of Western Ontario, would act as the coordinating centre for our Canadian Clinical Trial Network.
The infrastructure of this network is currently being established, and future investment will go directly into breakthrough clinical trial research. Already, there are many shortlisted trials under the CCTN that have been designed to enable commercialization within the near to medium term. The network has also succeeded in attracting global interest in conducting research at Canadian hospitals and universities. As an example, the Immune Tolerance Network, a non-profit, government-funded alliance of researchers working to establish new treatments for diseases of the immune system and based in the United States, has partnered with the CCTN to conduct trials here in Canada.
The CCTN has also received proposals for the expansion of a number of clinical trials started abroad, trials that would not have been conducted in Canada without the leadership of the CCTN. It's important to note that the Clinical Trial Network is not disease-specific; the platform serves as a template that is accessible by other disease researchers, organizations, and funders, and promotes other disease research through commercialization.
Companies and organizations around the world have already recognized Canada's leadership and expressed an interest in using the Clinical Trial Network as a model for clinical trial work abroad. The CCTN model has attracted the attention of JDRF Canada's global counterparts. JDRF Australia has been granted $5 million from the Australian government to emulate the CCTN. An interest in adopting similar networks has also been expressed by the JDRF in Europe, India, and Israel. In addition to attracting global interest and conducting research at our hospitals and universities, the CCTN is creating highly skilled jobs in Canada and contributing to the shift towards a knowledge-based economy.
JDRF's partnership with the Federal Economic Development Agency for Southern Ontario, and the federal government more broadly, is a concrete example of the important role that research excellence and scientific success plays in improving the competitiveness and productivity of our economy while also serving as a means to achieve a better standard of living for all Canadians. It also emphasizes the importance of direct government investment in research and development and commitment to public-private partnerships that lead to real societal gains and economic gains.
This is why this year JDRF is urging the committee to recommend that the federal government continue supporting our science and technology industries through a significant and sustained commitment to partnerships between private and public sectors that promote cutting-edge research, innovation, and commercialization. New treatments and scientific discoveries for diabetes is a proud Canadian legacy, and through JDRF's historic partnership with the government we will continue to work to bring it to new heights.
We are very pleased with what we have achieved today and hope that success for our unique funding partnership with the federal government will prompt the continuation of support and growth of Canadian science and technology industries through significant and sustained commitment to partnerships between the public and private sectors.
Thank you for your time today, and I'd be happy to answer any questions you may have.